Dean Ho,
Professor and Co-Director,
University of California-Los Angeles
Dr. Dean Ho is currently Professor in the Division of Oral Biology and Medicine and Department of Bioengineering, and Co-Director of the Weintraub Center for Reconstructive Biotechnology at the UCLA School of Dentistry. He was previously an Associate Professor of Biomedical and Mechanical Engineering at Northwestern University. Dr. Ho’s team pioneered the development of nanodiamonds for a spectrum of biomedical applications, and notably, NDX, a nanodiamond-doxorubicin complex based upon the potent drug interaction mediated by the diamond facets. NDX administration resulted in a marked enhancement in drug efficacy and reduced toxicity over clinical standards and was preclinically validated in multiple drug-resistant cancer models. Dr. Ho and collaborators are currently developing patient-specific phenotypic personalized medicine platforms that can optimize efficacy and safety towards a broad spectrum of diseases. Dr. Ho is a recipient of the NSF CAREER Award, Wallace H. Coulter Foundation Translational Research Award, V Foundation for Cancer Research V Scholar Award, John G. Bollinger Outstanding Young Manufacturing Engineer Award, IADR Young Investigator Award, and was named a Distinguished Young Alumnus of the UCLA School of Engineering. Ho was also named the inaugural SLAS Endowed Fellow. Dr. Ho is Editor-in-Chief of the Journal of Laboratory Automation and will serve as Chair of the Scientific Advisory Board in 2015.
Phenotypic Personalized Medicine: Merging Nanomedicine with Engineering Optimization Platforms to Transform Combination Therapy
Monday, 28 September 2015 at 14:00
Add to Calendar ▼2015-09-28 14:00:002015-09-28 15:00:00Europe/LondonPhenotypic Personalized Medicine: Merging Nanomedicine with Engineering Optimization Platforms to Transform Combination TherapyPoint-of-Care Diagnostics and Global Health World Congress in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Nanodiamonds have emerged as promising agents for drug delivery and imaging due to their unique surface properties. Nanodiamond-anthracycline compounds have mediated major improvements to drug delivery efficacy and safety. Most recently, NDX, a nanodiamond-doxorubicin agent, markedly enhanced the pre-clinical treatment efficacy of multiple drug-resistant tumor models with no apparent myelosuppression, demonstrating potent drug binding and the absence of early drug release. The combination of these pre-clinical advancements in diamond-based nanomedicine and nanodiamond surface properties serves as a foundation for a promising developmental roadmap that will be discussed. More recently, or team has focused on the integration of nano-modified and unmodified drug administration towards improved combination therapy via engineering optimization platforms. More specifically, we have developed a Phenotypic Personalized Medicine (PPM)-based platform for the mechanism-independent optimization of combination therapy towards a broad spectrum of diseases. The translational progress of the PPM platform will be highlighted.
Add to Calendar ▼2015-09-28 00:00:002015-09-30 00:00:00Europe/LondonPoint-of-Care Diagnostics and Global Health World CongressPoint-of-Care Diagnostics and Global Health World Congress in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2015-09-28 14:00:002015-09-28 15:00:00Europe/LondonPhenotypic Personalized Medicine: Merging Nanomedicine with Engineering Optimization Platforms to Transform Combination TherapyPoint-of-Care Diagnostics and Global Health World Congress in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
